Merestinib

Merestinib
INN: Merestinib
Clinical data
Routes of
administration
PO
ATC code
  • none
Identifiers
CAS Number
ChemSpider
Chemical and physical data
Formula C30H22F2N6O3
Molar mass 552.54 g·mol−1
3D model (JSmol)

Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.

Meristinib is part of a phase II clinical trial for advanced billiary tract cancer. The study is expected to be complete in April 2018.[1] Phase II clinical trials for non-small cell lung cancer and solid tumors began in November 2016.[2]

References

  1. "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer - Full Text View - ClinicalTrials.gov".
  2. "Merestinib - Eli Lilly - AdisInsight". adisinsight.springer.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.